Kura Oncology (KURA) Convertible Debt (2014)

Kura Oncology's (KURA) quarterly Convertible Debt came in at $500000.0 in Q4 2014.

Kura Oncology (KURA) Convertible Debt (2014) Analysis & Trends

Kura Oncology (KURA) has 1 years of Convertible Debt data on file, last reported at $500000.0 in Q4 2014.

On a quarterly basis, Convertible Debt changed N/A year-over-year to $500000.0 in Q4 2014; TTM through Dec 2014 was $500000.0, a N/A change from a year earlier, with the FY2014 full-year figure at $500000.0, changed N/A from the prior year.
Convertible Debt for Q4 2014 stood at $500000.0.
Over the last five years, Convertible Debt for KURA reached as high as $500000.0 in Q4 2014 and fell as low as $500000.0 in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Kura Oncology	925.97 Mn	925.97 Mn	18.00 Mn

Historic Data

Download Data

Date	Value
Dec 31, 2014	500,000.00